Pharmaceutical Executive
Pharmaceutical Executive: December 2025
Volume: 45
Issue: 9
Pharmaceutical Executive: October 2025
Volume: 45
Issue: 8
Pharmaceutical Executive: September 2025
Volume: 45
Issue: 7
Pharmaceutical Executive: August 2025
Volume: 45
Issue: 6
Pharmaceutical Executive: June 2025
Volume: 45
Issue: 5
Pharmaceutical Executive: May 2025
Volume: 45
Issue: 4
Pharmaceutical Executive: April 2025
Volume: 45
Issue: 3
Pharmaceutical Executive: March 2025
Volume: 45
Issue: 2
Pharmaceutical Executive: February 2025
Volume: 45
Issue: 1
Pharmaceutical Executive: December 2024
Volume: 44
Issue: 12
Pharmaceutical Executive: November 2024
Volume: 44
Issue: 11
Pharmaceutical Executive: October 2024
Volume: 44
Issue: 10
Pharmaceutical Executive: September 2024
Volume: 44
Issue: 9
Pharmaceutical Executive: July/August 2024
Volume: 44
Issue: 7/8
Pharmaceutical Executive: June 2024
Volume: 44
Issue: 6
Pharmaceutical Executive: May 2024
Volume: 44
Issue: 5
Pharmaceutical Executive: April 2024
Volume: 44
Issue: 4
Pharmaceutical Executive: March 2024
Volume: 44
Issue: 3
Pharmaceutical Executive: February 2024
Volume: 44
Issue: 1
Pharmaceutical Executive: December 2023
Volume: 43
Issue: 12
Pharmaceutical Executive: November 2023
Volume: 43
Issue: 11
Pharmaceutical Executive: October 2023
Volume: 43
Issue: 10
Pharmaceutical Executive: September 2023
Volume: 43
Issue: 9
Pharmaceutical Executive: August 2023
Volume: 43
Issue: 8
Pharmaceutical Executive: July 2023
Volume: 43
Issue: 7
Pharmaceutical Executive: June 2023
Volume: 43
Issue: 6
Pharmaceutical Executive: May 2023
Volume: 43
Issue: 5
Pharmaceutical Executive: April 2023
Volume: 43
Issue: 4
Pharmaceutical Executive: March 2023
Volume: 43
Issue: 3
Pharmaceutical Executive: February 2023
Volume: 43
Issue: 02
Advertisement
Advertisement
Trending on PharmExec
1
President Trump Announces Nine More TrumpRx Participants
2
Eli Lilly Announces Topline Results From Phase III Trial Studying Oral GLP-1 Therapy Orforglipron
3
Pfizer’s Stock Reacts to Decreases in 2026 Revenue Projections in Full-Year 2026 Guidance Release
4
BioMarin Reaches $4.8 Billion Definitive Agreement to Acquire Amicus Therapeutics
5